Daiichi Sankyo And Aussie Biotech Biota Begin Phase III Asian Trials For Second-Generation Flu Drug

PERTH, Australia - Daiichi Sankyo and Australian partner Biota have begun pivotal Phase III trials for anti-influenza drug CS-8958 in Japan, Taiwan, Hong Kong and Korea